| Name | Title | Contact Details |
|---|
Nihon Kohden America is a global leader and fast-growing manufacturer of instrumentation for Patient Monitoring, Sleep Assessment, Neurology and Cardiology. Our relentless dedication to quality, customer support with heart, and employee development are what makes us unique.
Xodus Medical is a New Kensington, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Spectrum Medical is a Gretna, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pacific Artisan Labs holds our commitment to quality and passion for the latest technology at the core of our process. Our independent lab network is able to be drastically differently, move nimbly, and respond to what our customers need. We build long-term relationships with our partners and continue to refine our techniques, tools, and lenses as true artistic expressions of skill with a goal to improve the practices we work with and the patients they serve. Guided by a passion for the craft of lens design and desire to do things differently, Brandon Butler founded Pacific Artisan Labs early in 2018. His rich experience in the industry and focus on quality makes him uniquely equipped to serve as President and CEO. United by our mission to team up with optometrists and ophthalmologists in their pursuit of excellence, our lab technicians create the quality difference in our lenses. PAL`s lab staff includes some of the most talented artisans in the optical industry. Our team is what separates PAL from every other lab in the network. Any lab can have great designs, top-notch equipment, and good prices; but without the best talent, the latest tech is pointless. That`s why PAL only works with the best of the best. We`re an independent lab and our culture reflects that breakaway from the corporate mold. Innovative and creative, our team joined PAL to contribute to the maker revolution. We`re curious artists, skilled technicians, driven data analysts, and inventive strategists.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.